Solid Biosciences (SLDB) CTO sells 3,616 shares after RSU vesting

Rhea-AI Filing Summary

Solid Biosciences Inc. Chief Technology Officer Paul Herzich reported both an RSU vesting and a related stock sale. On February 13, 2026, he acquired 7,187 shares of common stock upon the exercise of 7,187 restricted stock units at $0.00 per share, increasing his direct common stock holdings to 76,254 shares.

On February 18, 2026, Herzich then sold 3,616 common shares in an open-market transaction at a weighted average price of $5.8233 per share, with actual prices ranging from $5.23 to $6.14. The company states this sale was solely to cover tax withholding following RSU vesting, under a pre-established automatic sales instruction, and does not represent a discretionary trade by Herzich. After the sale, he directly held 72,638 common shares.

Insider Trade Summary

Net Seller: 3,616 shares ($21,057)

Net Sell 3 txns

Insider Herzich Paul

Role Chief Technology Officer

Sold 3,616 shs ($21K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,616	$5.8233	$21K
Exercise	Restricted Stock Units	7,187	$0.00	--
Exercise	Common Stock	7,187	$0.00	--

Holdings After Transaction: Common Stock — 72,638 shares (Direct); Restricted Stock Units — 14,376 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Mr. Herzich on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Herzich. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.23 to $6.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form. The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Herzich Paul

(Last) (First) (Middle)

C/O SOLID BIOSCIENCES INC.

500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)

CHARLESTOWN MA 02129

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/13/2026		M		7,187	A	(1)	76,254	D
Common Stock	02/18/2026		S		3,616(2)	D	$5.8233(3)	72,638	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/13/2026		M			7,187	(4)	(4)	Common Stock	7,187	$0.00	14,376	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

2. This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Mr. Herzich on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Herzich.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.23 to $6.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.

4. The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

	/s/ Kimberly Cornwell as attorney-in-fact for Paul Herzich	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Solid Biosciences (SLDB) report for Paul Herzich?

Solid Biosciences reported that CTO Paul Herzich acquired 7,187 common shares via RSU vesting and later sold 3,616 shares in the open market. The sale was executed to cover tax withholding related to the RSUs under a pre-established automatic sales instruction.

How many Solid Biosciences (SLDB) shares did Paul Herzich sell and at what price?

Paul Herzich sold 3,616 shares of common stock on February 18, 2026 at a weighted average price of $5.8233 per share. The shares were sold in multiple trades within a price range of $5.23 to $6.14, according to the filing.

Was the Solid Biosciences (SLDB) stock sale by CTO Paul Herzich discretionary?

The filing states the stock sale was not discretionary. It was made solely to cover withholding taxes after RSU vesting, executed under a durable automatic sales instruction letter that implements a sell-to-cover election previously adopted by Herzich on August 16, 2024.

How many Solid Biosciences (SLDB) shares does Paul Herzich own after these transactions?

After the reported transactions, Paul Herzich directly holds 72,638 shares of Solid Biosciences common stock. This reflects the net result of acquiring 7,187 shares from RSU vesting on February 13, 2026 and selling 3,616 shares on February 18, 2026.

What are the key details of the RSUs held by Solid Biosciences (SLDB) CTO Paul Herzich?

Each RSU represents a right to receive one share of common stock. The RSUs were granted on February 13, 2024 and vest over four years, with 25% of the original RSU grant vesting on each anniversary of the grant date until the fourth anniversary.

How many restricted stock units did Solid Biosciences (SLDB) CTO Paul Herzich exercise?

On February 13, 2026, Paul Herzich exercised 7,187 restricted stock units, converting them into 7,187 shares of Solid Biosciences common stock at an exercise price of $0.00 per share. Following this transaction, he held 14,376 RSUs remaining, according to the filing.